18 December 2015


Stupid is as stupid does. That's a very old adage. During the various arguments on various sites with regard to Valeant and Turing and KaloBios, I've been adamant that the American public shouldn't be forced to pay remaining life's earnings just to access a life saving/altering generic drug just so that the acquirer, who paid a stupid price for the drug/company, can get back the stupid price and 10% (or so) return on the stupid price. The wonders of our not really free market health industry.

Finally, an industry mogul admits the truth:
Imprimis CEO Mark Baum said that even if Turing's other investors decided to remove Shkreli, that alone would not be enough to change the fortunes of Daraprim. While at Retrophin, Shkreli hiked the price of its key drug, Thiola for kidney stones, to $30 a pill from $1.50. That price has not changed since Shkreli left.

"Once Turing went and paid what it did to buy that drug, they were locked into raising the price," Baum said.

Stupid is as stupid does.

No comments: